Publications
March 2024 Frontiers in Gastroenterology 3
DOI: 10.3389/fgstr.2024.1372191
LicenseCC BY 4.0
Neoplasia detection in FIT positive screening colonoscopies compared with an age-controlled symptomatic cohort: a retrospective review
Neil O’Morain 1,2*, Roisin Stack 1,2, Jayne Doherty 1,2,Blathnaid Nolan 1, Parker Girod 1, Lakshman Kumar 1,2,Mark McCrossan 1, Elaine Joy 2, Orlaith Casey 2,Gareth Horgan 1 and Glen Doherty 1,21Centre for Colorectal Disease, St. Vincent’s University Hospital, Dublin, Ireland, 2School of Medicine,University College Dublin, Dublin, Ireland
Gastroenterology 152(5):S395. DOI: 10.1016/S0016-5085(17)31560-3
Investigation of the in Vitro Stability of Golimumab Levels to Determine Optimum Handling and Transport of Samples in the Randomized Controlled Study; GOAL-ARC
J. Sheridan, L. Egan, +9 authors G. Doherty
J Crohns Colitis. 2019 Oct 28;13(11):1365-1371.doi: 10.1093/ecco-jcc/jjz067.
DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis
Catherine R Rowan 1, Garret Cullen 1, Hugh E Mulcahy 1, Juliette Sheridan 1, Alan C Moss 2, Elizabeth J Ryan 1, Glen A Doherty 1
Gastroenterology. 2019 Mar;156(4):935-945.e1.doi: 10.1053/j.gastro.2018.11.030. Epub 2018 Nov 16.
Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases
Brona Wynne 1, Louise McHugh 1, Wei Gao 2, Denise Keegan 3, Kathryn Byrne 3, Catherine Rowan 3, Karen Hartery 3, Clemens Kirschbaum 2, Glen Doherty 3, Garret Cullen 3, Barbara Dooley 1, Hugh E Mulcahy 4
Journal of Crohn’s and Colitis, Volume 13, Issue Supplement_1, March 2019, Pages S308–S309, https://doi.org/10.1093/ecco-jcc/jjy222.525
Published:25 January 2019
P401 Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
J O’Connell, M S Ismail, M McCormack, P McDonagh, R Argue, N Breslin, V Crowley, G Cullen, G A Doherty, C Dunne, K Hartery, F MacCarthy, S McKiernan, H Mulcahy, A O’Connor, C O’Morain, B Ryan, J Sheridan, M Healy, D McNamara, D Kevans
Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1019-1026.doi: 10.1097/MEG.0000000000001177.
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
Jim O’Connell 1, Cathy Rowan 2, Roisin Stack 3, Grace Harkin 4, Vikrant Parihar 5, Grace Chan 6, Niall Breslin 7 3, Garret Cullen 7 8 9, Cara Dunne 1 7, Laurence Egan 10 4, Gavin Harewood 5 11, Jan Leyden 8 6 9, Finbar MacCarthy 1 7, Padraic MacMathuna 7 6, Nasir Mahmud 1 7, Susan McKiernan 1 7, Deirdre McNamara 7 2 9, Hugh Mulcahy 7 8, Frank Murray 5 11, Anthony O’Connor 7 10 9, Aoibhlinn O’Toole 5 11 9, Stephen Patchett 5 11, Barbara Ryan 7 3, Juliette Sheridan 2 8, Eoin Slattery 9, Glen Doherty 7 8 9, David Kevans 1 7 9
BMJ Open Gastroenterology. 2018 Jan 11;5(1):e000174. doi: 10.1136/bmjgast-2017-000174. eCollection 2018.
Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)
Juliette Sheridan 1, Carol Ann Coe 1, Peter Doran 2, Laurence Egan 3, Garret Cullen 1, David Kevans 4, Jan Leyden 5, Marie Galligan 2, Aoibhlinn O’Toole 6, Jane McCarthy 7, Glen Doherty 1
Aliment Pharmacol Ther. 2018 Aug;48(3):333-339.doi: 10.1111/apt.14834. Epub 2018 Jun 19.
Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study
C R Rowan 1, D Keegan, K Byrne 1, G Cullen 1, H E Mulcahy 1, J Sheridan 1, E J Ryan 1, A de Vries 2, G D’Haens 3, G A Doherty 1
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):978-985.doi: 10.1111/jdv.14105. Epub 2017 Feb 17.
Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study
J Clowry 1, J Sheridan 2, R Healy 3, S Deady 4, D Keegan 2, K Byrne 2, G Cullen 2, H Mulcahy 2, H Comber 4, A C Parnell 3, G Doherty 2, A Lally 1
Aliment Pharmacol Ther. 2017 Jan;45(2):376-378.doi: 10.1111/apt.13861.
Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis
K Hartery 1 2, S O’Reilly 1 2, D Houlihan 2 3, G Doherty 1 2, H Mulcahy 1 2, G Cullen 1 2, J Sheridan 1 2
Journal of Crohn’s and Colitis, Volume 11, Issue 8, August 2017, Pages 1025–1026, https://doi.org/10.1093/ecco-jcc/jjw214
Published:23 December 2016
Letter: Vedolizumab in Pregnancy
P582 Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohort
J. Doherty*, M. Buckley, G. Cullen, G. Horgan, H. Mulcahy, G. Doherty, J. Sheridan
St Vincent’s University Hospital and School of Medicine, University College Dublin, Centre for Colorectal Disease, Dublin 4, Ireland
P594 Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn’s disease
C.R. Rowan*1, A. Alakkari2, C. Moran3, J. O’Connell4, G. Cullen1, H. Mulcahy1, C. O’Morain2, D. McNamara2, J. Leyden5, P. MacMathuna5, A. O’Toole3, S. Patchett3, S. McKiernan4, D. Kevans4, G.A. Doherty1, B. Ryan2
1St Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland; 2Adelaide & Meath Hospital, Dublin, Incorporating The National Children’s Hospital, Department of Gastroenterology, Dublin, Ireland; 3Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland; 4St. James’ Hospital, Department of Gastroenterology, Dublin, Ireland; 5Mater Misericordiae University Hospital, Department of Gastroenterology, Dublin, Ireland
P470 DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in ulcerative colitis (ECCO 2019)
C. R. Rowan*1, G. Cullen1, H. E. Mulcahy1, J. Sheridan1, A. C. Moss2,3, E. J. Ryan1, G. A. Doherty1
1St.Vincent’s University Hospital, Center for Colorectal Disease, Dublin, Ireland, 2Beth Israel Deaconess Medical Center, Gastroenterology, Boston, USA, 3Harvard Medical School, Boston, USA
Abstract No: A-1084-0059-05058
Submitter: Ciara Egan
Presenter: Ciara Egan
Abstract Title: THE DUBLIN INFLAMMATORY BURDEN SCORE PREDICTS EARLY CLINICAL AND BIOCHEMICAL RESPONSE TO GOLIMUMAB TREATMENT IN UC; EARLY RESULTS OF THE GOAL-ARC STUDY
Authors: Egan C.1, Jones F.2, Sheridan J.3, Coe A.4, Doran P.5, Cullen G.6, Leyden J.7, Galligan M.8, Mccarthy J.9, O’Toole A.10, Kevans D.11, Egan L.12, Doherty G.A.5
Institutes: 1University College Dublin, Dr, Dublin, Ireland, 2St. VIncent’s University Hospital, Dublin, Gastroenterology, Dublin, Ireland, 3St. Vincent´s University Hospital Beaumont University Hospital, Dublin, Ireland, 4St.Vincents University Hospital, Dublin, Ireland, 5University College Dublin, Dublin, Ireland, 6St. Vincent´s Hospital, Dublin, Ireland, 7Mater Misericordiae University Hospital, dublin, Ireland, 8University College Dublin, dublin, Ireland, 9Mercy university hospital, Gastro, cork, Ireland, 10Beaumont Hospital, Dublin, Ireland, 11St James’s University Hospital, Dublin, Ireland, 12NUI Galway – Dept. of Pharmacology, NUI Galway ; Galway/IE – Pharmacology, NUI Galway – Dept. of Pha, Pharmacology, Galway, Ireland
Abstract No: A-1084-0054-03404
Submitter: Dina Danso-Abeam
Presenter: Dina Danso-Abeam
Abstract Title: NON-CLASSICAL MONOCYTES ARE DECREASED FROM THE PERIPHERAL BLOOD OF ANTI-TNF NAÏVE ULCERATIVE COLITIS PATIENTS.
Authors: Danso-Abeam D.1, Walshe M.1, Tosetto M.1, Ardiff E.2, Coe C.1, Ryan E.J.1, Doherty G.A.3
Institutes: 1St. Vincent’s University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 2Dublin City University, Dublin, Ireland, 3University College Dublin, Dublin, Ireland